AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27986796 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential dysfunction
Number of subjects: 0
Study 27986796 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional CVD risk factors and elevated HbA
Number of subjects: 0
Study 27988497 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately reduced kidney function (eGFR 30 to 60 mL/min per 1.73 m²)
Number of subjects: 13102
Study 27988497 — intervention group
Group type: COMPARATOR
Intervention: Normal kidney function (eGFR >60 mL/min per 1.73 m²)
Number of subjects: 13102
Study 27989041 — intervention group
Group type: EXPERIMENTAL
Intervention: PMVR (MitraClip device)
Number of subjects: 26
Study 27989576 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 132030
Study 27989576 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive adults (not on ART)
Number of subjects: 132030
Study 27989576 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive adults in west Uganda
Number of subjects: 132030
Study 27989576 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive adults in east Uganda
Number of subjects: 132030
Study 27989576 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive adults in Kenya
Number of subjects: 132030
Study 27989576 — intervention group
Group type: COMPARATOR
Intervention: Serodiscordant couples in Uganda
Number of subjects: 132030
Study 27989576 — intervention group
Group type: COMPARATOR
Intervention: Serodiscordant couples in Kenya
Number of subjects: 132030
Study 27989789 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high rate cutoff programming (VH-RATE group: monitor zone 170-219 beats/min; ventricular fibrillation zone ≥220 beats/min with 13 ± 4 detection intervals)
Number of subjects: 2000
Study 27989789 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high rate cutoff programming (VH-RATE group)
Number of subjects: 2000
Study 27989789 — intervention group
Group type: COMPARATOR
Intervention: Control group (programmed with 1 or 2 therapy zones)
Number of subjects: 2000
Study 27989885 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcaval access for TAVR
Number of subjects: 100
Study 27989886 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of rosuvastatin daily for 8 to 12 weeks
Number of subjects: 85
Study 27992268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab induction followed by consolidation
Number of subjects: 152
Study 27992268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab consolidation
Number of subjects: 152
Study 27992268 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy
Number of subjects: 152
Study 27992451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID with Vinorelbine 30 mg/m2 IV days 1,8 every 21 days
Number of subjects: 27
Study 27992493 — intervention group
Group type: EXPERIMENTAL
Intervention: T1.5DM
Number of subjects: 140
Study 27992493 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 140
Study 27992691 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 157
Study 27992691 — intervention group
Group type: COMPARATOR
Intervention: MTX plus infliximab
Number of subjects: 157
Study 27993231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 99
Study 27993231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Risk (HR)
Number of subjects: 99
Study 27993231 — intervention group
Group type: COMPARATOR
Intervention: Low-Risk (LR)
Number of subjects: 99
Study 27993573 — intervention group
Group type: COMPARATOR
Intervention: Blood-based age/sex/gene expression score (ASGES) low (ASGES ≤15)
Number of subjects: 566
Study 27993573 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based age/sex/gene expression score (ASGES) elevated (ASGES >15)
Number of subjects: 566
Study 27993904 — intervention group
Group type: EXPERIMENTAL
Intervention: CPET after treatment of iliofemoral occlusive arterial disease
Number of subjects: 30
Study 27993904 — intervention group
Group type: COMPARATOR
Intervention: CPET before treatment of iliofemoral occlusive arterial disease
Number of subjects: 30
Study 27993903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise two-photon excited melanin fluorescence
Number of subjects: 620
Study 27993926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized LDL (ox-LDL) quartiles (2nd, 3rd, and 4th)
Number of subjects: 3987
Study 27993926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized LDL (ox-LDL)
Number of subjects: 3987
Study 27993926 — intervention group
Group type: COMPARATOR
Intervention: HOMA-IR (HOMA-insulin resistance)
Number of subjects: 3987
Study 27995182 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy Progression Score (CoPS) assessment
Number of subjects: 0
Study 27995485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 0.5%/salicylic acid 10%
Number of subjects: 166
Study 27995485 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 166
Study 27995580 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab in combination with doxorubicin
Number of subjects: 0
Study 27995580 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab
Number of subjects: 0
Study 27996967 — intervention group
Group type: EXPERIMENTAL
Intervention: AdhAQP1 administration
Number of subjects: 5
Study 27997989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention program (diet and moderate exercise) for 16 weeks
Number of subjects: 16
Study 27998223 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 93
Study 27998970 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 on day 1, Cisplatin 50 mg/m2 on day 2, Veliparib escalating doses from 50 to 400 mg orally two times daily on days 1-7
Number of subjects: 34
Study 27998970 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Cisplatin with Veliparib
Number of subjects: 34
Study 27999035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous intermittent dosing (ID) of vancomycin
Number of subjects: 32
Study 27999035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing (CD) of vancomycin
Number of subjects: 32
Study 27999035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin therapy (general)
Number of subjects: 32
Study 27999038 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 (50, 100, 150 or 200 mg)
Number of subjects: 24
Study 27999038 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464
Number of subjects: 24
Study 27999038 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464-NGlc
Number of subjects: 24
Study 27999040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administered before surgical incision, before cessation of CPB, and after surgery.
Number of subjects: 56
Study 27999040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin dosing regimen with an additional bolus dose at the start of CPB.
Number of subjects: 56
Study 27999040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin dosing regimen during prolonged surgery with preserved renal function.
Number of subjects: 56
Study 27999607 — intervention group
Group type: EXPERIMENTAL
Intervention: Loquat Leaf Extract (500 mg, 50.94 mg of Ursolic Acid)
Number of subjects: 54
Study 27999607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27999663 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 130
Study 27999663 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical matched patients)
Number of subjects: 130
Study 27999670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy group treatment
Number of subjects: 47
Study 28000140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose-sensing technology
Number of subjects: 224
Study 28000140 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 224
Study 28000190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) combined with soluble dietary fiber (pectin, 8 g/d) and probiotics (bifid triple viable capsules, twice per day) for 4 weeks after initial treatment with vancomycin 500 mg orally twice per day for 3 days.
Number of subjects: 23
Study 28000375 — intervention group
Group type: EXPERIMENTAL
Intervention: iDXA
Number of subjects: 93
Study 28000375 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 93
Study 28003133 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial induction (MI) intervention focused on the upper limb area following the Pilat approach, 30 minutes per session.
Number of subjects: 21
Study 28003133 — intervention group
Group type: COMPARATOR
Intervention: Placebo pulsed shortwave therapy (control group), 30 minutes per session.
Number of subjects: 21
Study 28003218 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmatic early treatment success
Number of subjects: 1333
Study 28003218 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator-assessed early treatment success
Number of subjects: 1333
Study 28003248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-facilitated, mobile phone-based clinical decision support system-enabled intervention
Number of subjects: 6797
Study 28003301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual video-microscopy
Number of subjects: 15
Study 28004304 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Number of subjects: 64
Study 28004304 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 64
Study 28004304 — intervention group
Group type: COMPARATOR
Intervention: Weight-stable controls
Number of subjects: 64
Study 28004360 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive adipose graft transposition procedure (mi-AGTP) by thoracoscopy
Number of subjects: 0
Study 28005959 — intervention group
Group type: EXPERIMENTAL
Intervention: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 1 x 30 μg, 2 x 30 μg, 2 x 15 μg
Number of subjects: 0
Study 28005959 — intervention group
Group type: EXPERIMENTAL
Intervention: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine)
Number of subjects: 0
Study 28005959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28005959 — intervention group
Group type: EXPERIMENTAL
Intervention: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 2 doses vs 1 dose
Number of subjects: 0
Study 28006063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (2 mg) every 8 weeks after 5 monthly doses with sham injections on nontreatment visits starting at week 24.
Number of subjects: 109
Study 28006063 — intervention group
Group type: COMPARATOR
Intervention: Laser control (no treatment).
Number of subjects: 109
Study 28007027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with vancomycin-loaded calcium sulfate and vancomycin-loaded PMMA
Number of subjects: 51
Study 28007027 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic-loaded PMMA (Control Group)
Number of subjects: 51
Study 28007090 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge chamber (ACC) exposure to ragweed pollen (RW)
Number of subjects: 201
Study 28007445 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, person-directed, structured program delivered by an interprofessional team (occupational therapist, registered nurse, handyman)
Number of subjects: 226
Study 28007445 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, person-directed, structured program delivered by an interprofessional team
Number of subjects: 226
Study 28007690 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI tractography-assisted stereotactic surgery targeting the DRT in general anesthesia
Number of subjects: 24
Study 28007690 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic surgery of the thalamic/subthalamic region as conventionally used
Number of subjects: 24
Study 28007741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided drug-eluting stents implantation with ASM
Number of subjects: 2072
Study 28007741 — intervention group
Group type: COMPARATOR
Intervention: Intravascular ultrasound-guided drug-eluting stents implantation without ASM
Number of subjects: 2072
Study 28008698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients recorded in primary care (PC) but never hospitalized
Number of subjects: 89554
Study 28008698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in hospital admissions but not known in PC
Number of subjects: 89554
Study 28008698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients known in both contexts (PC and hospital admissions)
Number of subjects: 89554
Study 28008698 — intervention group
Group type: COMPARATOR
Intervention: General population (age- and sex-matched)
Number of subjects: 89554
Study 28009526 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient Thelarche (TT)
Number of subjects: 98
Study 28009526 — intervention group
Group type: COMPARATOR
Intervention: Normal progression
Number of subjects: 98
Study 28009526 — intervention group
Group type: EXPERIMENTAL
Intervention: First (transient) thelarche
Number of subjects: 98
Study 28009745 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymph node dissection (MILND)
Number of subjects: 87
Study 28010726 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 25
Study 28011051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (TMZ) at a daily dose of 75 mg/m²
Number of subjects: 50
Study 28011051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (TMZ)
Number of subjects: 50
Study 28011397 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-methoxy-catalposide
Number of subjects: 0
Study 28011608 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Mycobacterium abscessus lung disease
Number of subjects: 67
Study 28011903 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine
Number of subjects: 81
Study 28011903 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP
Number of subjects: 81
Study 28011903 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab maintenance therapy
Number of subjects: 81
Study 28011903 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during induction
Number of subjects: 81
Study 28012074 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable mitral annuloplasty ring
Number of subjects: 45
Study 28012300 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 84
Study 28012300 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 84
Study 28012677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 100
Study 28012848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescently labeled peptide (76.4 μmol/L) administered topically to proximal colon
Number of subjects: 63
Study 28012848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescently labeled peptide (2.25 μmol/L and 76.4 μmol/L) administered topically to proximal colon
Number of subjects: 63
Study 28012848 — intervention group
Group type: COMPARATOR
Intervention: Fluorescently labeled peptide
Number of subjects: 63
Study 28013265 — intervention group
Group type: EXPERIMENTAL
Intervention: High drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Number of subjects: 101
Study 28013265 — intervention group
Group type: COMPARATOR
Intervention: Low drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Number of subjects: 101
Study 28013354 — intervention group
Group type: EXPERIMENTAL
Intervention: High GABA
Number of subjects: 0
Study 28013354 — intervention group
Group type: COMPARATOR
Intervention: Non-selective GABA
Number of subjects: 0
Study 28013405 — intervention group
Group type: EXPERIMENTAL
Intervention: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) administered via intratumoral convection-enhanced delivery for 72 hours.
Number of subjects: 0
Study 28013450 — intervention group
Group type: EXPERIMENTAL
Intervention: abiliti® closed-loop GES system (CLGES)
Number of subjects: 97
Study 28017350 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT ≥ 14 ng/l
Number of subjects: 1279
Study 28017350 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT < 14 ng/l, overweight
Number of subjects: 1279
Study 28017350 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT < 14 ng/l, obese
Number of subjects: 1279
Study 28017350 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT ≥ 14 ng/l, overweight
Number of subjects: 1279
Study 28017350 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT ≥ 14 ng/l, obese
Number of subjects: 1279
Study 28017384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging
Number of subjects: 203
Study 28017714 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 134
Study 28017714 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 134
Study 28017967 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib
Number of subjects: 0
Study 28017967 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib and Venetoclax combination
Number of subjects: 0
Study 28018669 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-clopidogrel combination
Number of subjects: 0
Study 28018669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole-clopidogrel combination
Number of subjects: 0
Study 28018669 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 0
Study 28018871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention including self-management support and patient-centred motivational approaches
Number of subjects: 332
Study 28025328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in BOREALIN gene (p.S148F, p.R114Q, p.L177W)
Number of subjects: 134
Study 28025328 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of BOREALIN mutants in human thyrocytes
Number of subjects: 134
Study 28025328 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression pattern in thyroid tissue of patient with BOREALIN-p.R114W
Number of subjects: 134
Study 28025359 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported self-management intervention (IMPPRESS)
Number of subjects: 26
Study 28025627 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28025928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care using the Dader Method
Number of subjects: 92
Study 28025928 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 28027590 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 62
Study 28027850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 136
Study 28027850 — intervention group
Group type: COMPARATOR
Intervention: MRI before PCI
Number of subjects: 136
Study 28028584 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 538
Study 28028584 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 538
Study 28029055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hsTnT, NT-proBNP, and hsCRP with the GRACE score
Number of subjects: 1892
Study 28029055 — intervention group
Group type: COMPARATOR
Intervention: Conventional versus high sensitivity troponin assay
Number of subjects: 1892
Study 28029055 — intervention group
Group type: COMPARATOR
Intervention: Novel biomarkers (PlGF, sFlt-1, sFlt-1/PlGF ratio)
Number of subjects: 1892
Study 28029055 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality at 30 days
Number of subjects: 1892
Study 28029055 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality at 1 year
Number of subjects: 1892
Study 28029383 — intervention group
Group type: EXPERIMENTAL
Intervention: M-BET (multicomponent behavioral treatment and exercise therapy)
Number of subjects: 72
Study 28029383 — intervention group
Group type: COMPARATOR
Intervention: α-blocker (tamsulosin, 0.4-mg tablet nightly)
Number of subjects: 72
Study 28029383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (M-BET + α-blocker)
Number of subjects: 72
Study 28029529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) plus sofosbuvir (400 mg) fixed-dose combination tablet once daily for 6 weeks
Number of subjects: 20
Study 28029529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir plus sofosbuvir
Number of subjects: 20
Study 28029746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alström syndrome cohort
Number of subjects: 38
Study 28029918 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (20 to 30 mg/m², administered twice daily on a continuous dosing schedule in 28-day cycles)
Number of subjects: 24
Study 28029927 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-engineered T cells targeting IL13Rα2, administered multiple times over 220 days through intracranial delivery routes.
Number of subjects: 1
Study 28030441 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypoxaemia during ECMO
Number of subjects: 7
Study 28030555 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling (30 minutes, 6 days/week)
Number of subjects: 33
Study 28030578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple non-invasive tools including ECG, NT-proBNP, SO2, and WHO functional class I-II
Number of subjects: 394
Study 28030578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of non-right axis deviation, NT-proBNP<333pg/ml, SO2≥95.5%, and WHO functional class I-II
Number of subjects: 394
Study 28030578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple non-invasive tools
Number of subjects: 394
Study 28030579 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg and Deleobuvir 600 mg (Child-Pugh A) or 400 mg (Child-Pugh B) twice-daily with weight-based ribavirin for 24 weeks
Number of subjects: 35
Study 28030579 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir + Deleobuvir + Ribavirin
Number of subjects: 35
Study 28031192 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) 2010
Number of subjects: 1336